|
Number of Patients
|
652
|
184
|
18
|
|
Centre
|
|
Cambridge
|
228 (35.0%)
|
58 (31.5%)
|
5 (27.8%)
|
|
Manchester
|
424 (65.0%)
|
126 (68.5%)
|
13 (72.2%)
|
|
Age at index, mean (SD)
|
64.84 (10.5)
|
62.97 (10.3)
|
65.06 (8.9)
|
|
< 70 years, n (%)
|
424 (65.0%)
|
130 (70.7%)
|
13 (72.2%)
|
|
≥ 70 years, n (%)
|
228 (35.0%)
|
54 (29.4%)
|
5 (27.8%)
|
|
Male, n (%)
|
426 (65.3%)
|
124 (67.4%)
|
14 (77.8%)
|
|
Weight (kg), mean (SD)
|
78.12 (17.5)
|
79.99 (17.8)
|
77.92 (12.6)
|
|
Missing, n (%)
|
243 (37.3%)
|
57 (31.0%)
|
6 (33.3%)
|
|
Histological subtype, n (%)
|
|
Clear cell
|
518 (79.5%)
|
141 (76.6%)
|
13 (72.2%)
|
|
Non-clear cell
|
70 (10.7%)
|
28 (15.2%)
|
4 (22.2%)
|
|
Other
|
22 (3.4%)
|
5 (2.7%)
|
1 (5.6%)
|
|
MSKCC prognostic risk score (at time of LOT initiation), n(%)
|
|
Favourable
|
73 (11.2%)
|
27 (14.7%)
|
2 (11.1%)
|
|
Intermediate
|
380 (58.3%)
|
77 (41.9%)
|
11 (61.1%)
|
|
Poor
|
174 (26.7%)
|
59 (32.1%)
|
2 (11.1%)
|
|
Missing
|
25 (3.8%)
|
21 (11.4%)
| |
|
Ethnicity, n (%)
|
|
White
|
629 (96.5%)
|
176 (95.7%)
|
17 (94.4%)
|
|
Black
|
4 (0.6%)
|
2 (1.1%)
|
0 (0.0%)
|
|
Asian (Chinese/other)
|
1 (0.2%)
|
1 (0.5%)
|
0 (0.0%)
|
|
Asian (South-East Asian)
|
15 (2.3%)
|
5 (2.7%)
|
1 (5.6%)
|
|
Mixed
|
0 (0.0%)
|
0 (0.0%)
|
0 (0.0%)
|
|
Other
|
3 (0.5%)
|
0 (0.0%)
|
0 (0.0%)
|
|
Comorbidity (History of), n (%)
|
|
Hypertension
|
200 (30.7%)
|
55 (29.9%)
|
8 (44.4%)
|
|
T1DM
|
5 (0.8%)
|
1 (0.5%)
|
0 (0.0%)
|
|
T2DM
|
78 (12.0%)
|
27 (14.7%)
|
0 (0.0%)
|
|
CAD
|
29 (4.5%)
|
4 (2.2%)
|
0 (0.0%)
|
|
Congestive HF
|
4 (0.6%)
|
0 (0.0%)
|
0 (0.0%)
|
|
Hypothyroidism
|
21 (3.2%)
|
6 (3.3%)
|
1 (5.6%)
|
|
VTE
|
6 (0.9%)
|
1 (0.5%)
|
0 (0.0%)
|
|
Autoimmune disease
|
1 (0.2%)
|
0 (0.0%)
|
0 (0.0%)
|
|
Conditions involving regular corticosteroid therapy
|
5 (0.78%)
|
0 (0.0%)
|
0 (0.0%)
|
|
Other
|
229 (35.1%)
|
62 (33.7%)
|
5 (27.8%)
|
